217 related articles for article (PubMed ID: 35689826)
1. Human FOXP3 and tumour microenvironment.
Wang J; Gong R; Zhao C; Lei K; Sun X; Ren H
Immunology; 2023 Feb; 168(2):248-255. PubMed ID: 35689826
[TBL] [Abstract][Full Text] [Related]
2. FOXP3: A Player of Immunogenetic Architecture in Lung Cancer.
Ziółkowska-Suchanek I; Żurawek M
Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674427
[TBL] [Abstract][Full Text] [Related]
3. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
[TBL] [Abstract][Full Text] [Related]
4. Higher densities of Foxp3
Yeong J; Thike AA; Lim JC; Lee B; Li H; Wong SC; Hue SS; Tan PH; Iqbal J
Breast Cancer Res Treat; 2017 May; 163(1):21-35. PubMed ID: 28233108
[TBL] [Abstract][Full Text] [Related]
5. Regulatory T cells, especially ICOS
Tu JF; Ding YH; Ying XH; Wu FZ; Zhou XM; Zhang DK; Zou H; Ji JS
Sci Rep; 2016 Oct; 6():35056. PubMed ID: 27725696
[TBL] [Abstract][Full Text] [Related]
6. FoxP3
Saleh R; Elkord E
Cancer Lett; 2020 Oct; 490():174-185. PubMed ID: 32721551
[TBL] [Abstract][Full Text] [Related]
7. FOXP3/HAT1 Axis Controls Treg Infiltration in the Tumor Microenvironment by Inducing CCR4 Expression in Breast Cancer.
Sarkar T; Dhar S; Chakraborty D; Pati S; Bose S; Panda AK; Basak U; Chakraborty S; Mukherjee S; Guin A; Jana K; Sarkar DK; Sa G
Front Immunol; 2022; 13():740588. PubMed ID: 35222362
[TBL] [Abstract][Full Text] [Related]
8. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.
Li F; Sun Y; Huang J; Xu W; Liu J; Yuan Z
Cancer Med; 2019 Dec; 8(17):7330-7344. PubMed ID: 31631566
[TBL] [Abstract][Full Text] [Related]
9. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells.
Tao H; Mimura Y; Aoe K; Kobayashi S; Yamamoto H; Matsuda E; Okabe K; Matsumoto T; Sugi K; Ueoka H
Lung Cancer; 2012 Jan; 75(1):95-101. PubMed ID: 21719142
[TBL] [Abstract][Full Text] [Related]
10. Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.
Revenko A; Carnevalli LS; Sinclair C; Johnson B; Peter A; Taylor M; Hettrick L; Chapman M; Klein S; Solanki A; Gattis D; Watt A; Hughes AM; Magiera L; Kar G; Ireland L; Mele DA; Sah V; Singh M; Walton J; Mairesse M; King M; Edbrooke M; Lyne P; Barry ST; Fawell S; Goldberg FW; MacLeod AR
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35387780
[TBL] [Abstract][Full Text] [Related]
11. High FoxP3 expression in tumour cells predicts better survival in gastric cancer and its role in tumour microenvironment.
Ma GF; Miao Q; Liu YM; Gao H; Lian JJ; Wang YN; Zeng XQ; Luo TC; Ma LL; Shen ZB; Sun YH; Chen SY
Br J Cancer; 2014 Mar; 110(6):1552-60. PubMed ID: 24548868
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous and oral squamous cell carcinoma-dual immunosuppression via recruitment of FOXP3+ regulatory T cells and endogenous tumour FOXP3 expression?
Schipmann S; Wermker K; Schulze HJ; Kleinheinz J; Brunner G
J Craniomaxillofac Surg; 2014 Dec; 42(8):1827-33. PubMed ID: 25087653
[TBL] [Abstract][Full Text] [Related]
13. FOXP3 (in)stability and cancer immunotherapy.
Mortezaee K
Cytokine; 2024 Jun; 178():156589. PubMed ID: 38547750
[TBL] [Abstract][Full Text] [Related]
14. FOXP3+ Tregs: heterogeneous phenotypes and conflicting impacts on survival outcomes in patients with colorectal cancer.
Zhuo C; Xu Y; Ying M; Li Q; Huang L; Li D; Cai S; Li B
Immunol Res; 2015 Mar; 61(3):338-47. PubMed ID: 25608795
[TBL] [Abstract][Full Text] [Related]
15. Accumulation of FoxP3+ T regulatory cells in the tumor microenvironment of human colorectal adenomas.
Hua W; Yuan A; Zheng W; Li C; Cui J; Pang Z; Zhang L; Li Z; Goll R; Cui G
Pathol Res Pract; 2016 Feb; 212(2):106-12. PubMed ID: 26724144
[TBL] [Abstract][Full Text] [Related]
16. The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in malignant melanoma - an immunohistochemical study.
Salmi S; Lin A; Hirschovits-Gerz B; Valkonen M; Aaltonen N; Sironen R; Siiskonen H; Pasonen-Seppänen S
BMC Cancer; 2021 May; 21(1):641. PubMed ID: 34051744
[TBL] [Abstract][Full Text] [Related]
17. Association of tumour-infiltrating regulatory T cells with adverse outcomes in dogs with malignant tumours.
Sakai K; Maeda S; Yamada Y; Chambers JK; Uchida K; Nakayama H; Yonezawa T; Matsuki N
Vet Comp Oncol; 2018 Sep; 16(3):330-336. PubMed ID: 29322606
[TBL] [Abstract][Full Text] [Related]
18. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer.
Shimizu K; Nakata M; Hirami Y; Yukawa T; Maeda A; Tanemoto K
J Thorac Oncol; 2010 May; 5(5):585-90. PubMed ID: 20234320
[TBL] [Abstract][Full Text] [Related]
19. Tumour infiltrating CD25+ FoxP3+ regulatory T cells (Tregs) relate to tumour grade and stromal inflammation in oral squamous cell carcinoma.
Al-Qahtani D; Anil S; Rajendran R
J Oral Pathol Med; 2011 Sep; 40(8):636-42. PubMed ID: 21352381
[TBL] [Abstract][Full Text] [Related]
20. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
